Third Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INC

Financial Performance:

• Q3 2026 revenue was $13.2 million, a 74% increase year-over-year from $7.6 million, driven by the ongoing collaboration agreement with GSK.
• Research and Development (R&D) expenses increased to $53.8 million in Q3 2026 compared to $45.9 million in the prior year quarter, reflecting investment in advancing clinical programs including the Phase 2 portion of the INLIGHT study and the RNA editing pipeline.
• General and Administrative (G&A) expenses rose to $25.4 million from $18.1 million in the prior year quarter, supporting pipeline advancement and preparation for future development stages.
• Net loss for Q3 2026 was $61.9 million, compared to $53.9 million in the prior year quarter.
• The company ended the quarter with $431 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into Q3 2028.
• A $12 million milestone payment from GSK is expected in Q4 2026 following their selection of a development candidate.

Guidance and Future Outlook:

• The company is on track to initiate a Phase 2a post-incretin maintenance trial for WVE-007 in Q4 2026 to prevent weight regain.
• WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD) is advancing toward a single registrational trial with a potential path to full approval without a separate confirmatory study, based on FDA alignment.
• WVE-008 for PNPLA3 liver disease remains on track for a Clinical Trial Application (CTA) submission in 2026.
• 600 mg data from the Phase 1 MAD portion of the INLIGHT study is expected in Q4 2026 to further characterize potency, duration, and safety.
• Data from the 600 mg monthly dosing cohort of the Restoration 2 trial for WVE-006 will be shared in Q4 2026 to inform dose selection for the pivotal study.
• Initial data readouts from the Phase 2a monotherapy trial for WVE-007 are anticipated to begin emerging later in the year, with 3-month or 6-month interim analyses planned.

Business Segments and Product Lines:

• WVE-007 (Inhibin E siRNA for Obesity): Advancing in monotherapy (Phase 2a for BMI 35-50 with comorbidities), combination therapy (with trisepatide for BMI 35-50 + T2D), and maintenance settings. Preclinical and Phase 1 data demonstrate substantial visceral fat loss with lean mass preservation and durable suppression supporting 1-2 times yearly dosing.
• WVE-006 (RNA Editing for AATD): Aiming to treat both lung and liver manifestations by restoring dynamic AAT levels; current IV augmentation only treats lung issues and depletes during inflammation. The company plans a single two-year registrational trial with a one-year interim analysis for accelerated approval.
• WVE-008 (RNA Editing for PNPLA3): Correcting the I148M variant to restore normal liver function rather than silencing the gene, targeting 9 million homozygous carriers in the US and Europe.
• GSK Collaboration: GSK selected an siRNA development candidate from the SPINA design portfolio to transition into their pipeline, validating WAVE's technology.
• New Leadership: Monica Vinuk joined as Chief Business Officer to expand corporate development and platform licensing opportunities.

Market and Competitive Landscape:

• Obesity Market: WVE-007 positions itself as a differentiated alternative to GLP-1s by preventing muscle loss (up to 40% of weight loss with current standards) and addressing the high rate of weight regain (up to 70%) post-cessation of incretin therapies.
• AATD Market: WAVE's RNA editing approach offers a first-line therapy that treats both lung and liver disease, contrasting with silencing approaches that only reduce liver load or leave the lung unprotected, and avoiding the safety/payer hurdles of DNA editing.
• Regulatory Environment: Management notes a shift toward evaluating "healthy weight loss" based on body composition (visceral fat reduction, lean mass preservation) rather than total scale weight.
• Rare Disease Hub: FDA engagement suggests potential for harmonized approval pathways for genetic medicines, allowing WAVE's single-trial design for AATD.

Risks and Challenges:

• Clinical Execution: Reliance on meeting specific regulatory thresholds (e.g., >5% weight loss at 12 months) and achieving MZ-like phenotype for AATD approval.
• Safety Profile: Ensuring tolerability and safety for chronic dosing in obesity, particularly regarding muscle preservation claims and potential off-target effects.
• Competitive Pressure: Differentiating against established incretin therapies and emerging competitors in the siRNA and editing spaces (e.g., Arrowhead, Takeda).
• Forward-Looking Statements: Risks related to the uncertainty of achieving clinical endpoints, regulatory approvals, and the ability to secure future milestones or partnerships.

Management Commentary and Tone:

• Management conveyed high confidence in the proprietary SPINA chemistry and RNA editing platform, citing the Nobel Prize in Chemistry (chirality) as validation of their focus on stereochemistry.
• Tone was optimistic about the potential to redefine obesity treatment by preserving muscle and preventing weight regain, viewing the current GLP-1 landscape as having clear unmet needs.
• Management emphasized the strategic value of the GSK collaboration and the "mutually beneficial" nature of the partnership despite past portfolio adjustments.
• Paul Bolno and Chris Wright highlighted the efficiency of their drug discovery process (e.g., 18 months from mouse to human data for WVE-007).

Analyst Questions and Answers:

• AATD Approval Pathway: FDA confirmed the single trial design could lead to both accelerated and full approval based on biomarkers (restoring MZ-like phenotype) without a separate confirmatory trial. FEV1 is deemed infeasible for the primary endpoint; CD densitometry and exacerbation rates are being considered.
• WVE-007 Body Composition: Higher baseline adiposity in Phase 2a patients is expected to yield more pronounced fat loss. Management remains confident in reaching the 5% weight loss threshold while preserving lean mass.
• Dosing Strategies: WVE-007 maintenance dosing may require different regimens than induction, potentially lower doses to prevent fat regain. WVE-006 600mg data will help model the optimal dosing interval (potentially less frequent than monthly).
• FDA Assay Flexibility: FDA was comfortable with WAVE's proprietary LC-MS assays for AATD, allowing for consistent biomarker measurement throughout development.
• GSK Relationship: The relationship is described as evolving positively, with GSK's new leadership aligning with WAVE's platform capabilities to unlock difficult targets.
• EU Strategy: WAVE anticipates a potential rapid path to the EU market for AATD, leveraging EU acceptance of CT densitometry as a primary endpoint.

Other Key Points:

• Upcoming Research Day will feature Dr. Arun Sanyal discussing PNPLA3 liver disease and further details on the company's chemistry across hepatic and extrahepatic modalities.
• WAVE is leveraging patient registries and foundations to accelerate enrollment for the AATD pivotal trial.
• The company is actively engaging with regulators and advocacy groups to shift the narrative from simple weight loss to body composition improvement in the obesity space.
• No further specific dates for the AATD pivotal trial enrollment were provided, pending finalization of the 600mg dosing data.